Femasys (NASDAQ:FEMY) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen downgraded shares of Femasys (NASDAQ:FEMY) from a sell rating to a strong sell rating in a report published on Sunday morning,Wall Street Zen reports.

Several other analysts have also issued reports on the company. Maxim Group dropped their target price on Femasys to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Lake Street Capital decreased their price target on Femasys to $10.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. Finally, Weiss Ratings downgraded Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Femasys Stock Performance

Shares of NASDAQ:FEMY opened at $1.37 on Friday. The company’s 50-day moving average price is $2.13 and its two-hundred day moving average price is $5.89. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.14 and a quick ratio of 0.55. Femasys has a one year low of $1.25 and a one year high of $22.20. The stock has a market capitalization of $11.48 million, a PE ratio of -0.39 and a beta of -2.13.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings data on Friday, August 14th. The company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.73 million. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.

About Femasys

Femasys Inc is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures.

Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.